Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Inclusion Criteria:

   - Males/females >/= 18 years

   - Patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for
   radical prostatectomy or patients with prostate tumor recurrence (Patients with
   advanced tumor disease and a high likelihood to display lymph node metastasis are to
   be preferably included.)

   - ECOG (Eastern Cooperative Oncology Group) performance status of 0-2, determined within
   one week prior to treatment with BAY94-9392

   - Patient had an [18F]-fluorodeoxyglucose (FDG) PET/CT for detection, or staging, or
   restaging, or therapy response assessment that still showed tumor mass with high
   certainty for a cancer such as melanoma, or colorectal cancer, or head & neck cancer
   for which FDG-PET/CT is used in clinical routine, and the primary cancer disease is
   histologically confirmed. In case of recurrent disease confirmation of the primary
   tumor is sufficient

   - No clinically relevant deviations in renal function as determined by Cockcroft and
   Gault method using serum creatinine at screening.

Exclusion Criteria:

   - Concurrent severe and/or uncontrolled and/or unstable medical disease other than
   cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure,
   myocardial infarction within 12 months prior to planned injection of BAY94-9392,
   unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe
   pulmonary disease) which could compromise participation in the study

   - Known sensitivity to the study drug or components of the preparation

   - Previous treatment with BAY94-9392 in this study